Archives
-
CD109, STAT3 and Chemoresistance in Colorectal Cancer
2026-10-06
A 2026 study identifies CD109 as a regulator of colorectal cancer stemness, chemotherapy resistance and metastatic colonization through an LRRC8A/AKAP12/PKCα–STAT3 signaling axis linked to WNT activity. Its integrated patient, cellular and mouse-model evidence supports CD109 as a mechanistic target, while also showing why the findings require validation across tumor genotypes and clinically relevant treatment settings.
-
AP1903 and Conditional Evidence in Cell Models
2026-10-06
AP1903 is an FKBP-binding ligand for controlled protein activation, apoptosis pathway research, and conditional cell ablation models. This article connects its evidence framework with multiplexed ACE2 receptor research while separating biochemical potency, cellular phenotype, and pseudotyped-virus entry compatibility.
-
NADPH Oxidase ROS Activate L-Type Ca2+ Channels
2026-10-05
Shvetsova and colleagues show that NADPH oxidase-derived reactive oxygen species promote contraction of saphenous arteries from early postnatal rats through L-type voltage-gated calcium channels. Pharmacological pathway dissection separates this response from Rho-kinase, protein kinase C, and Src-kinase signaling, while indicating that calcium-channel blockade does not suppress ROS production.
-
CHI3L1-IN-5: Evidence and Research Scope
2026-10-05
A source-grounded overview of Compound Z17, distinguishing reported mechanism claims from independently supported evidence and defining its current research scope and limitations.
-
ECL Western Blotting Substrate Overview
2026-10-04
ECL Western Blotting Substrate (SKU K2187) is described by APExBIO as a luminol-based, nonradioactive horseradish peroxidase detection reagent for protein detection by chemiluminescence in Western blot assays. No matched paper evidence was provided, so performance claims remain unverified.
-
ECL Western Blotting Substrate: Product Overview
2026-10-03
ECL Western Blotting Substrate, SKU K2187, is described by APExBIO as a luminol-based, nonradioactive horseradish peroxidase detection reagent for chemiluminescent Western blot assays. No matched paper evidence was available, so supplier claims are not independently validated here.
-
10 mM dNTP Mixture: PCR-Ready DNA Synthesis
2026-10-02
The 10 mM dNTP mixture is an equimolar aqueous stock containing dATP, dCTP, dGTP, and dTTP at 10 mM each. Its defined pH 7.0 formulation and storage recommendation at -20°C or below support standardized PCR, qPCR, sequencing, and other DNA synthesis workflows.
-
DiscoveryProbe FDA-approved Drug Library for LAG-3
2026-10-01
Explore how the DiscoveryProbe FDA-approved Drug Library supports mechanism-led LAG-3 research, from dual-ligand biochemical screening to cell-based validation. This article translates a landmark small-molecule study into practical decisions for drug repositioning screening and cancer research drug screening.
-
CP-673451: Selective PDGFRα/β Inhibitor
2026-10-01
CP-673451 combines nanomolar PDGFRα/β activity with a selectivity profile suited to pathway, angiogenesis, and tumor-model research. This practical guide explains how to build reproducible phosphorylation, cell-response, angiogenesis, and ATRX-stratified glioma workflows around the compound.
-
DiscoveryProbe FDA-approved Drug Library for AML
2026-09-30
Use the DiscoveryProbe FDA-approved Drug Library to move from broad compound screening to mechanism-led AML validation. Its pre-dissolved, clinically annotated collection supports efficient drug repositioning screening, high-content phenotyping, and target-focused follow-up without requiring de novo compound synthesis.
-
Gly-Gly-Phe-Gly (GGFG) Workflow Guide
2026-09-30
Gly-Gly-Phe-Gly is a compact, glycine-rich spacer for controlled drug conjugation research, peptide engineering, and biomaterial construction. This guide pairs practical GGFG handling and coupling workflows with assay-design lessons from a multiple-myeloma combination study, while clearly separating linker utility from disease-model evidence.
-
CDC42, NTCP, and HBV Entry: New Mechanistic Links
2026-09-29
The reference study identifies CDC42 as a regulator of hepatitis B virus entry through two connected but distinct mechanisms: Rab11-dependent delivery of NTCP to the plasma membrane and CDC42-dependent macropinocytosis. These findings refine the current model of HBV entry and suggest that host trafficking and actin-regulatory pathways may be relevant to antiviral research, while also defining important experimental controls for studying receptor localization and viral internalization.
-
Spiroplasma Entry into Drosophila S2 Cells
2026-09-29
Wei et al. established an invertebrate cell model showing that Spiroplasma eriocheiris enters Drosophila Schneider 2 cells through clathrin-mediated endocytosis and macropinocytosis, with additional dependence on actin filaments and microtubules. The study also separates these entry mechanisms from cholesterol-dependent caveola-like uptake and provides a practical inhibitor-based framework for investigating a poorly characterized crustacean pathogen.
-
Nicotinamide Riboside Chloride (NIAGEN) Research Guide
2026-09-28
Nicotinamide Riboside Chloride (NIAGEN) is a defined NAD+ precursor for studying cellular energy metabolism, sirtuin biology, and metabolic dysfunction. Evidence supports NAD-related biochemical activity and selected preclinical outcomes, but model-specific validation remains essential.
-
Cardamomin Limits Oxidative Injury in Stroke Models
2026-09-28
A study of cardamomin from Amomum villosum Lour. links antioxidant protection to MEK/ERK-associated NRF2 activation and reduced AIFM1-linked cell death in experimental models. Its combination of hydrogen peroxide-stressed BV-2 cells and permanent middle cerebral artery occlusion in rats provides mechanistic and tissue-level evidence, while leaving important questions about dosing, timing, and clinical relevance unresolved.